They designed a precision-targeted therapeutic system that can target CD24high cells by enhancing ferroptosis and macrophage phagocytosis through FSP1 and CD24 inhibition mediated by the NF2-YAP signaling axis, finally leading to cell death and hence inhibiting TNBC tumor growth and even disappearance of some tumors (122). This evidence concerns the gene YAP1 and neoplasm.